QDEL

8.3206.73%
JP

Jonathan P. Siegrist

Head of Point of Care Diagnostics

Mr. Jonathan P. Siegrist, Ph.D., is Head of Point of Care Diagnostics at QuidelOrtho Corporation from November 9, 2026. Mr. Siegrist served as Executive Vice President of Research & Development and Chief Technology Officer of QuidelOrtho Corporation since October 07, 2024 until November 9, 2026. He was CTO and Head of Assay R&D of Cepheid, Inc. He oversees the Innovation & Technology group at Cepheid, a global team focused on the development and launch of next-generation multiplex molecular diagnostics systems, software, consumables and assays. Mr. Siegrist serves as Scientific Advisor of iGlyko, Inc. As a co-founder of iGlyko, Mr. Siegrist is involved with laboratory work at iGlyko and provides significant part-time assistance with clinical testing and research and engineering tasks. Mr. Siegrist joined Dr. Marc Madou's group for research involving centrifugal microfluidic platforms for nucleic acid analysis. This includes the design, fabrication and testing of platforms for applications such as real-time analysis of anthrax and microarray scanning for sepsis diagnosis. His other research experience includes work in the Bioengineering Department of the Lawrence Berkeley National Lab and in the biochemistry R&D group at Gen-Probe, Inc. His undergraduate research at UCLA involved MEMS-based deep-brain stimulation probes for Parkinson's disease. He holds a B.S. in Electrical Engineering from UCLA and an M.S. and Ph.D. in Biomedical Engineering from UC Irvine.

Positions